**Core Concept**
Eptifibatide is a glycoprotein IIb/IIIa inhibitor, which means it selectively blocks the glycoprotein IIb/IIIa receptor on platelet membranes. This blockade prevents platelet aggregation by inhibiting the final common pathway of platelet activation, which is the binding of fibrinogen to the glycoprotein IIb/IIIa receptor.

**Why the Correct Answer is Right**
Eptifibatide is used in the treatment of acute coronary syndromes, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI). It is administered intravenously and works by directly inhibiting the glycoprotein IIb/IIIa receptor, which is essential for platelet aggregation. This action prevents the formation of a platelet plug and subsequent thrombus formation, thereby reducing the risk of recurrent ischemic events.

**Why Each Wrong Option is Incorrect**

**Option A:** This is incorrect because eptifibatide is not used for the treatment of atrial fibrillation. While anticoagulation may be necessary in this setting, eptifibatide is not the appropriate choice.

**Option B:** This is incorrect because eptifibatide is not used for the treatment of hypertension. While antihypertensive therapy is essential in managing cardiovascular disease, eptifibatide is not indicated for this purpose.

**Option C:** This is incorrect because eptifibatide is not used for the treatment of acute stroke. While thrombolytic therapy may be necessary in this setting, eptifibatide is not the appropriate choice.

**Clinical Pearl / High-Yield Fact**
Glycoprotein IIb/IIIa inhibitors like eptifibatide are a key component of the treatment of acute coronary syndromes. They work by directly inhibiting platelet aggregation, thereby reducing the risk of recurrent ischemic events.

**Correct Answer: C. Acute coronary syndromes, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI).**